- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
First Issue of Patient Care Online Digital Edition Goes Live
The inaugural digital issue of Patient Care focuses on the antiobesity and type 2 diabetes medications, semaglutide and tirzepatide.
The inaugural issue of the Patient Care Online digital edition is now live. The digital edition will be available monthly and offer a selection of the website's top ranked news and features, as measured by Patient Care reader interest and engagement.
This month's issue focuses on the popular antiobesity and type 2 diabetes (T2D) medications, semaglutide and tirzepatide, including findings from a recent study on the association of semaglutide with the risk of suicidal ideation in a real-world cohort, a closer look at which US states have the highest and lowest prescribing rates of glucagon-like peptide-1 (GLP-1) receptor agonist medications, and details on an open letter to the public from Eli Lilly warning against the use of tirzepatide for "cosmetic weight loss."
Find out more in the digital edition, here.
